Magnetic Nanoparticles and Their Potential for Contrast Enhancement in Magnetic Resonance Imaging

2012 ◽  
Vol 1 (1) ◽  
pp. 40-46 ◽  
Author(s):  
K. Witte ◽  
K. Porath ◽  
E. Burkel
Keyword(s):  
Magnetic Resonance Imaging ◽  
Magnetic Nanoparticles ◽  
Magnetic Resonance ◽  
Contrast Enhancement ◽  
Resonance Imaging

scholarly journals Magnetic Nanoparticles for Early Detection of Cancer by Magnetic Resonance Imaging

MRS Bulletin ◽  
2009 ◽  
Vol 34 (6) ◽  
pp. 441-448 ◽  
Author(s):  
Wenbin Lin ◽  
Taeghwan Hyeon ◽  
Gregory M. Lanza ◽  
Miqin Zhang ◽  
Thomas J. Meade
Keyword(s):  
Magnetic Resonance Imaging ◽  
Magnetic Nanoparticles ◽  
Magnetic Resonance ◽  
Early Detection ◽  
Contrast Agents ◽  
Contrast Enhancement ◽  
Negative Contrast ◽  
Mri Contrast Agents ◽  
Ferrite Nanoparticles ◽  
Resonance Imaging

AbstractThis article provides a brief overview of recent progress in the synthesis and functionalization of magnetic nanoparticles and their applications in the early detection of malignant tumors by magnetic resonance imaging (MRI). The intrinsic low sensitivity of MRI necessitates the use of large quantities of exogenous contrast agents in many imaging studies. Magnetic nanoparticles have recently emerged as highly efficient MRI contrast agents because these nanometer-scale materials can carry high payloads while maintaining the ability to move through physiological systems. Superparamagnetic ferrite nanoparticles (such as iron oxide) provide excellent negative contrast enhancement. Recent refinement of synthetic methodologies has led to ferrite nanoparticles with narrow size distributions and high crystallinity. Target-specific tumor imaging becomes possible through functionalization of ferrite nanoparticles with targeting agents to allow for site-specific accumulation. Nanoparticulate contrast agents capable of positive contrast enhancement have recently been developed in order to overcome the drawbacks of negative contrast enhancement afforded by ferrite nanoparticles. These newly developed magnetic nanoparticles have the potential to enable physicians to diagnose cancer at the earliest stage possible and thus can have an enormous impact on more effective cancer treatment.

Lipoma in olecranon bursa: A case report

2021 ◽  
Vol 3 ◽  
pp. 67-69
Author(s):  
Shalini Agarwal ◽  
Jyoti Siwach ◽  
Ramneet Wadi ◽  
Nipun Gupta
Keyword(s):  
Magnetic Resonance Imaging ◽  
Case Report ◽  
Magnetic Resonance ◽  
Contrast Enhancement ◽  
Local Anesthesia ◽  
Signal Intensity ◽  
Ultrasound Examination ◽  
Fat Cells ◽  
Resonance Imaging ◽  
Diffusion Weighted Images

We report a case of a 55-year-old male patient who presented with swelling over his right elbow of 5-year duration. An ultrasound examination revealed an echogenic mass within the olecranon bursa. On magnetic resonance imaging, the mass revealed the signal intensity of fat, and it was attached to the bursal lining by means of a pedicle. There was no restriction on diffusion-weighted images and no significant contrast enhancement. Excision was performed under local anesthesia. The excised specimen revealed mature fat cells on histopathology.

Magnetic Resonance Imaging of Brain Involvement in Dogs Using Paramagnetic Contrast Enhancement with Mn(II)-DCTA P

2016 ◽  
Vol 161 (5) ◽  
pp. 715-718
Author(s):  
W. Yu. Ussov ◽  
M. L. Belyanin ◽  
A. I. Bezlepkin ◽  
O. Yu. Borodin ◽  
E. E. Bobrikova ◽  
...  
Keyword(s):  
Magnetic Resonance Imaging ◽  
Magnetic Resonance ◽  
Contrast Enhancement ◽  
Resonance Imaging ◽  
Brain Involvement

Delayed Magnetic Resonance Imaging Contrast Enhancement of Synthetic Ventricular Septum

2006 ◽  
Vol 1 (6) ◽  
pp. 340-342
Author(s):  
Christopher L. Lindblade ◽  
Mervyn D. Cohen ◽  
Roger A. Hurwitz ◽  
Tiffanie R. Johnson
Keyword(s):  
Magnetic Resonance Imaging ◽  
Magnetic Resonance ◽  
Contrast Enhancement ◽  
Ventricular Septum ◽  
Resonance Imaging ◽  
Magnetic Resonance Imaging Contrast

scholarly journals NIMG-33. CHANGES IN MAGNETIC RESONANCE IMAGING AFTER PROTON BOOST THERAPY FOR GLIOBLASTOMA WITH AND WITHOUT TUMOR TREATING FIELDS THERAPY

2020 ◽  
Vol 22 (Supplement_2) ◽  
pp. ii155-ii155
Author(s):  
Hanna Goett ◽  
Alexandra Jensen ◽  
Tobias Struffert ◽  
Eberhard Uhl ◽  
Marco Stein
Keyword(s):  
Magnetic Resonance Imaging ◽  
Radiation Therapy ◽  
Magnetic Resonance ◽  
Contrast Enhancement ◽  
Median Overall Survival ◽  
Progressive Disease ◽  
Tumor Resection ◽  
Resonance Imaging ◽  
Tumor Treating Fields ◽  
Magnetic Resonance Imaging Mri

Abstract BACKGROUND Tumor treating fields (TTFields) are an approved glioblastoma (GBM) treatment modality that demonstrated a significant improved median overall survival in newly diagnosed GBM patients. Data about morphologic changes in serial magnetic resonance imaging (MRI) for patients with a combination therapy of TTFields and proton boost therapy does not exist. METHODS Twenty-two patients were included in this study. All patients were treated with initial tumor resection followed by combined chemo- and radiation therapy. Radiation therapy was performed with 50.0 Gy photons and a proton boost with 10 Gy equivalent (Gy(RBE)). 11 patients were additionally treated with TTFields. RESULTS A new increase in contrast enhancement and/or a progress in the T2 FLAIR hyperintensity was observed in 54.5% (N=12) at 3 months and in 31.8% (N=7) at 6 months. No differences were observed between patients with and without TTFields therapy at 3 months [63.6% (N=7) vs. 45.5% (N=5); P=0.392] and at 6 months [27.3 (N=3) vs. 36.3% (N=4); P=0.647). By the RANO criteria a progressive disease (PD) was observed in 6 patients (27.3%) at 3 months and in 7 patients (31.8%) at 6 months. Pseudoprogression (PP) was observed in in 36.4% (N=8) at months and in 27.3% (N=6) at 6 months. Neither for PD at 3 months [36.4% (N=4) vs. 18.2% (N=2); P=0.338] or at 6 months [36.4% (N=4) vs. 27.3% (N=3); P=0.647), nor for PP at 3 months [45.5% (N=5) vs. 27.2% (N=3); P=0.375] or at 6 months [18.2% (N=2) vs. 36.4% (N=4); P=0.338] differences for patients with and without TTFields therapy were found. CONCLUSION Increased contrast enhancement and/or increased T2 FLAIR MRI hyperintensity after proton boost therapy are common. Furthermore, the rates for new contrast enhancement, PD, and PP after photon therapy with and without additional TTFields therapy are comparable.

Sign in / Sign up

Export Citation Format

Share Document